Back to Search
Start Over
Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares.
Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares.
- Source :
-
Journal of translational autoimmunity [J Transl Autoimmun] 2024 Jun 20; Vol. 9, pp. 100244. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Lupus nephritis (LN) diagnosis and follow-up requires noninvasive biomarkers. Therefore, the added value of coupling the urinary soluble (s)CD163/creatinuria ratio with serological markers was evaluated in a real-world clinical practice. To this end, a monocentric and retrospective study was conducted in 139 SLE patients with biopsy-proven nephritis having an active LN (LN-A, n = 63 with a positive SLEDAI-renal score) or inactive (n = 76), as well as 98 non-renal SLE patients. The urinary sCD163/creatinuria ratio outperformed serological markers for predicting LN-A (AUC>0.972; p < 10 <superscript>-4</superscript> with a 100 % specificity threshold fixed at 320 ng/mmol), and for monitoring renal activity allowing prediction of impending flares and remissions in follow-up (AUC = 0.789, p < 10 <superscript>-4</superscript> ). LN-A patients with an elevated spot proteinuria/creatinuria ratio (p = 8 × 10 <superscript>-6</superscript> ) and sCD163/creatinuria ratio (p = 10 <superscript>-3</superscript> ) were at risk for developing end-stage kidney disease but sCD163/creatinuria ratio cannot substitute kidney biopsy to discriminate LN-A from other glomerulonephritis. Among serological markers (n = 14), anti-dsDNA and anti-C1q antibodies (Abs) (AUC>0.750 versus non-LN patients, and AUC>0.640 versus LN-IR patients) best predicted LN-A, and higher levels were retrieved in class III/IV proliferative LN-A. In multivariate logistic regression analysis, the urinary sCD163/creatinuria ratio remained the only statistically significant biomarker to predict LN-A (p < 0.001). In conclusion, and as compared to classical serological markers, the urinary sCD163/creatinuria ratio provides an additional parameter for monitoring LN patients.<br />Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (© 2024 The Authors. Published by Elsevier B.V.)
Details
- Language :
- English
- ISSN :
- 2589-9090
- Volume :
- 9
- Database :
- MEDLINE
- Journal :
- Journal of translational autoimmunity
- Publication Type :
- Academic Journal
- Accession number :
- 39021518
- Full Text :
- https://doi.org/10.1016/j.jtauto.2024.100244